Stock Detail
BIONOVO INC
Biotechnology
BNVI @ Yahoo Finance | BNVI Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $0.36 | $0.42 | $-0.03 | -7.69% | 0.00 | $0.39 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $0.42 | $0.35 | 722,392 | 19.64M | 137,381 | -0.80 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 0.45 | 0.41 | 0.38 | 0.34 | 0.31 |
Stock Profile
Bionovo, Inc. engages in the discovery and development of drugs in the areas of cancer and women's health primarily in the United States. It develops drugs to treat breast and ovarian cancers, and for menopause. The company's product and drug pipeline includes MF101, a selective estrogen receptor beta agonist, which is in Phase II trial to alleviate the symptoms of menopause, including hot flashes, night sweats, and bone mineral loss; and BZL101, an apoptosis inducing factor translocator/activator, which completed Phase I clinical trial, is an anticancer agent for breast, pancreatic, and ovarian cancers, and used for the treatment of other solid tumors. Its preclinical drug pipeline includes AA102, an apoptosis inducer, which would be used as an anticancer agent that attenuates mitochodrial membrane potential to cause a cytochrome c release and caspase activation to induce apoptosis; and VG101, an intra-vaginal gel for the treatment of postmenopausal vaginal dryness. The company has collaboration with the University of California at San Francisco; University of California at Berkeley; University of California at Davis; University of Texas, Southwestern; and University of Colorado Health Sciences College. Bionovo was founded in 2002 and is headquartered in Emeryville, California.